Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Immuron’s filings can feel like dissecting a lab notebook—hundreds of pages of trial protocols, FDA correspondence, and funding disclosures buried in dense language. Every 10-K details how its hyper-immune bovine colostrum platform and flagship product Travelan® drive revenue, while risk factors dive deep into clinical uncertainty. If you are searching “Immuron SEC filings explained simply” or “how to read Immuron’s annual report 10-K,” you are not alone.
Stock Titan’s AI turns that complexity into clarity. Our engine maps each section of the Immuron quarterly earnings report 10-Q filing, flags shifts in R&D expenditure, and delivers real-time alerts the moment an 8-K material event is posted. Need “Immuron insider trading Form 4 transactions” or “Immuron executive stock transactions Form 4” in real time? We surface them within seconds, complete with plain-English summaries that spotlight buying and selling trends. You can even ask, “understanding Immuron SEC documents with AI,” and receive distilled insights, key metrics, and side-by-side comparisons across reporting periods.
The result is actionable context you will not find on EDGAR alone. Track pipeline milestones hidden in 8-Ks, scrutinize cash runway from the latest 10-Q, or examine board pay via the proxy statement executive compensation tables—all without wading through biotech jargon. Whether you monitor “Immuron earnings report filing analysis” or want its “Immuron annual report 10-K simplified,” this page delivers every filing type, continuously updated, so you can focus on investment decisions, not document hunting.
Immuron Limited furnished a Form 6-K to provide investors with an Australian Securities Exchange announcement dated October 21, 2025. The filing attaches Exhibit 99.1 titled “Presentation to AusBiotech Invest 2025 Conference.”
The material is furnished, not filed, under the Exchange Act and is not incorporated by reference into other securities filings unless specifically referenced. This update primarily shares the presentation made available to the market.
Immuron Limited furnished a Form 6‑K that attaches two Australian Securities Exchange announcements. The notices, dated October 20, 2025, are titled “Application for quotation of securities - IMC” and “Cleansing Notice.”
The company states this Form 6‑K, including the exhibits, is being furnished and is not deemed “filed” under the Exchange Act, and it is not incorporated by reference into other filings unless expressly referenced.
Immuron Limited furnished a Form 6-K announcing that it published two announcements to the Australian Securities Exchange on October 17, 2025. The filing attaches these ASX items and highlights an exhibit titled “Proposed issue of securities - IMC.”
The company states this 6-K, including the exhibit, is furnished and not deemed filed under the Exchange Act, and will not be incorporated by reference into Securities Act filings unless specifically referenced.
FAQ
What is the current stock price of Immuron (IMRN)?
What is the market cap of Immuron (IMRN)?
